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Abstract
Background: To date, the complexity of the plasma proteome exceeds the analytical capacity of conventional approaches
to isolate lower abundance proteins that may prove to be informative biomarkers. Only complex multistep separation
strategies have been able to detect a substantial number of low abundance proteins (,100 ng/ml). The first step of these
protocols is generally the depletion of high abundance proteins by the use of immunoaffinity columns or, alternatively, the
enrichment of by the use of solid phase hexapeptides ligand libraries.
Methodology/Principal Findings: Here we present a direct comparison of these two approaches. Following either
approach, the plasma sample was further fractionated by SCX chromatography and analyzed by RP-LC-MS/MS with a Q-TOF
mass spectrometer. The depletion of the 20 most abundant plasma proteins allowed the identification of about 25% more
proteins than those detectable following low abundance proteins enrichment. The two datasets are partially overlapping
and the identified proteins belong to the same order of magnitude in terms of plasma concentration.
Conclusions/Significance: Our results show that the two approaches give complementary results. However, the enrichment
of low abundance proteins has the great advantage of obtaining much larger amount of material that can be used for
further fractionations and analyses and emerges also as a cheaper and technically simpler approach. Collectively, these data
indicate that the enrichment approach seems more suitable as the first stage of a complex multi-step fractionation protocol.
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Introduction
The human blood is a rich source for biomarker discovery.
Plasma is usually preferred over serum for the lower ex vivo protein
degradation [1,2].
A comprehensive, systematic characterization of plasma pro-
teome in healthy and diseased states could greatly facilitate the
detection of biomarkers for early disease diagnosis, prognosis and
therapeutic monitoring. Chances of finding a new biomarker
increase with the number of proteins profiled; the most promising
source of biomarkers is probably the fraction of low abundant
proteins that either leak into the plasma from tissues as a result of
disease or play a role as cellular ligands and signal molecules.
However, characterization of the human plasma proteome is a
very difficult task: the top ten most abundant plasma proteins
account for approximately 90% of the total protein content, while
other proteins are present in a very wide dynamic range, spanning
more than 10 orders of magnitude in terms of concentration [3].
This last feature, in particular, makes the plasma proteome
the most complex human-derived proteome. In fact, current
shotgun proteomic technologies a r ea b l et od e t e c ta n di d e n t i f y
extremely small amounts of proteins (in the femtomole to
attomole range), but have difficulties in detecting and quanti-
fying proteins present at two to three orders of magnitude lower
than the most abundant ones. Hence, extensive fractionation is
indispensable to reduce the dynamic range and enhance the
coverage of the plasma proteome. The recent review of
Hoffman et al. [4] describes the increasingly complex
approaches that have been developed over time, starting with
single-step protocols (leading to the identification of ,100
proteins), to more complex 4-step protocols (where over 2000
proteins could be identified). This trend is confirmed by works
published after 2007 [5–8].
Since the analysis of plasma proteome necessarily requires a
multidimensional approach, it is particularly important to
optimize each step, in order to get the best results.
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immunodepletion of high abundance proteins (HAPs), a step that
is necessary for detection of low abundance proteins (LAPs).
Several studies on the efficiency, reproducibility and non-
specific binding of different depletion products have been already
published [6,9–21]. The majority of these studies, however, only
assessed HSA or HSA and IgG removal [10,11,14,19,21].
During the last years, there has been a gradual development of
several multiple affinity removal columns for the simultaneous
depletion of even more HAPs, able to retain 7 (e.g. the MARS Hu-
7 kit by Agilent Technologies), 14 (e.g. the Seppro IgY14 kit by
Sigma Aldrich or the MARS Hu-14 kit by Agilent Technologies)
and 20 HAPs (e.g. the ProteoPrep20 by Sigma).
Analternative and innovative strategyto isolate LAPsis based onthe
treatment of complex protein samples with a large, highly diverse
library of hexapeptides bound to a chromatographic support
(ProteoMiner technology, BioRad). In theory, each unique hexapep-
tide binds to a unique protein recognition site. Since HAPs saturate
their ligands, exceeding proteins are washed out during the procedure.
In contrast, LAPs are concentrated on their specific ligands, thereby
decreasing the dynamic range of proteins in the sample [22].
The literature is actually limited in comparing these two major
approaches:to the best of our knowledge, there are currentlyonlyfive
published papers comparing HAPs depletion and LAPs enrichment
[8,23–26], and none of them included the ProteoPrep20 which
immunocaptures the highest number of HAPs and therefore should
be considered the more efficient currently available depletion system.
From the literature, it appears that depletion of only HSA and IgG is
less efficient compared to the use of peptide ligand affinity beads [25].
The literature is inconsistent and controversial in the comparison
between more complex multi-depletion systems and LAPs enrich-
ment approach. In fact, some authors state that removal of up to 12
[8] and 14 [23,24] HAPs gives a similar performance as LAPs
enrichment, while other authors [26] showed that MARS Hu-7
depletion kit performance surpassed that of ProteoMiner.
Manyof the above mentioned studies concerning the comparison
between different depletion systems or the comparison between
depletion and enrichment methods were conducted using 2-DE.
The evaluation criterion was based on the number of visualized
spots in the gel, without giving information of protein identities.
This way of comparing performances is misleading, considering
that the high abundant proteins in the plasma are also present in
many different isoforms that appear as different spots in a 2D gel.
Therefore, a higher number of spots visible on a gel could be
indicative of an incomplete or partial depletion rather then of a more
efficient depletion. Conversely, it is essential to identify the proteins
and classify them according to protein families in order to compare
the real capacity of the depletion or the enrichment methods, to
remove the highly abundant proteins or enrich the low abundant
ones. For these reasons, in order to compare depletion and
enrichment methods, we have decided to use a gel-free approach.
The aim of this study was to determine which method between
HAPs depletion and LAPs enrichment provides the best overall
results in terms of number of identified proteins, protein coverage
and enhanced sensitivity limit. In particular, for the first time, we
compared the results obtained using ProteoMiner to those
obtained using ProteoPrep20, which is currently the deepest
depletion spin column kit commercially available.
Materials and Methods
All chemicals used in this study were of sequencing grade and
were purchased from Sigma (St. Louis, MO, USA) unless
otherwise specified.
Plasma sample
The protocol was approved by the Ethics Committee of the
Medical Faculty at the University of Padova, Italy, and was
performed according to the Helsinki Declaration (1983 revision).
The human blood sample was harvested in EDTA collection tubes
by a healthy donor who provided a written informed consent.
After centrifugation at 1500 RCF for 10 min, plasma was
separated from blood cells and a cocktail of protease inhibitors
(AEBSF, Sigma-Aldrich, St. Louis, USA) was added. Plasma was
stored at 220uC until use.
HAP depletion procedure
ProteoPrep20 depletion. The ProteoPrep20 immunodepl-
etion spin column technology (PROT20S-1KIT, Sigma-Aldrich,
MO, USA) employs a mixture of antibodies against the following
20 human plasma HAPs: albumin, transferrin, alpha-1 acid
glycoprotein, Complement (C1q, C3, C4), Ig (G, A, M, D),
fibrinogen, ceruloplasmin, alpha-2-macroglobulin, alpha-1-
antitrypsin, apolipoprotein (A-1, A-II, B), plasminogen,
haptoglobin, prealbumin. According to the manufacturer
instructions, 8 ml of plasma sample were diluted to 100 ml with
PBS, filtered (0.2 mm) through a Corning Spin-X Centrifuge Tube
Filter, added to the immunoaffinity spin column (previously
equilibrated in PBS) and incubated at room temperature for
20 min. The column was then centrifuged at 1500 RCF for 1 min
and the flow-through (depleted plasma) was collected in a clean
tube. The remaining unbound proteins were further washed from
the spin column by adding 100 ml of PBS and collected in the
same tube by centrifugation. This washing step was repeated
twice. Sample was concentrated with an Ultrafree-MC
microcentrifuge filters to a final volume of 125 ml. The column
was finally regenerated by removing the bound proteins with 2 ml
of Elution Solution (0.1 M Glycine-HCl, pH 2.5, and TWEEN
20) as specified by the manufacturer. The column was stored at
5uC in 5 ml of Equilibration Buffer (phosphate buffered saline)
with the addition of 10 ml of ProteoPrep Preservative Concentrate.
Multi-step depletion approach: combination of
ProteoExtract and ProteoPrep20 depletion
HSA and IgG depletion using the ProteoExtract kit (1
st passage)
(ProteoExtract Albumin/IgG removal kit, catalog #122642,
Calbiochem, EMD Biosciences, CA, USA) was performed as
previously described [27]. Briefly, 60 ml of plasma were diluted in
400 ml of sodium phosphate buffer 0.1 M pH 7.5, applied to the
affinity column, to accomplish the specific binding of HSA and
IgG and the eluate was collected together with 1200 ml of sodium
phosphate buffer 0.1 M pH 7.5, used to wash the column. The
HSA- and IgG-free sample was concentrated to 300 ml with
Vivaspin 500 centrifugal concentrators and further depleted
(100 ml at a time) using the ProteoPrep20 column as described
above, loading 100 ml at a time (2
nd passage). The 3 fractions
eluted from the ProteoPrep20 column were pooled and concen-
trated with Vivaspin 500 down to 100 ml. Finally, these 100 ml
were depleted one more time with ProteoPrep20 (3
rd passage).
LAP enrichment procedure. LAPs enrichment was
performed using the ProteoMiner technology (ProteoMiner
Introductory kit, catalog #163-3001, BioRad, CA, USA), which
is based on a combinatorial library of hexapeptides bound to a
chromatographic support. According to the manufacturer
instructions, storage solution was removed by centrifugation at
1000 RCF for 2 min and the bead column was washed first with
deionized water and then with 25 mM phosphate buffer, pH 7.4.
1 ml of plasma was added to the column and incubated at room
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centrifugation and the column was washed three times with
25 mM phosphate buffer, pH 7.4 and once with deionized water.
Bound proteins were incubated for 15 min and sequentially eluted
with with 100 ml of elution buffer 1 (7 M urea, 2 M thiourea and
3% CHAPS) and 100 ml of elution buffer 2 (9 M urea in 50 mM
acetic acid or citric acid, pH 3.3, 2% CHAPS). Finally, the two
eluted samples were pooled and analysed.
Protein precipitation, quantification and tryptic
digestion. Proteins obtained by the different fractionation
methods were precipitated in four volumes of cold acetone
(100%) overnight at 220uC. Samples were then centrifuged at
14000 RCF for 10 min and pellets were dissolved in 100 mlo f
20 mM ammonium bicarbonate. Protein concentration was
determined by a Lowry assay [28]. Proteins were incubated
overnight at 37uC with sequencing grade trypsin (Promega,
Madison, WI, USA) and with an enzyme to substrate ratio of 1:20
(w/w).
Strong Cation Exchange peptide fractionation. After
tryptic digestion, SCX fractionation was performed using a
cation exchange cartridge (AB Sciex, Toronto, Canada).
Samples were diluted to 500 ml in equilibration buffer (5 mM
KH2PO4, 25% acetonitrile, pH 3), adjusting the pH with 1 M
H3PO4. Peptides were loaded onto the cartridge at 50 ml/min and
extensive washing was performed with 1 ml of equilibration buffer.
Peptides were fractionated and stepwise eluted using each time
500 ml of elution buffer (5 mM KH2PO4, 25% acetonitrile, pH 3,
with the addition of 50, 100, 150, 200 and 350 mM KCl). Peptide
fractions were dried under vacuum, resuspended in 1 ml of 0.1%
formic acid and desalted with C18 cartridges (Strata,
Phenomenex) according to the manufacturer instructions.
Desalted samples were finally dried under vacuum, dissolved in
20 ml of 0.1% formic acid and analyzed by LC-MS/MS.
Reversed-phase LC-MS/MS analyses. Peptides obtained
by SCX fractionation were analyzed by LC-MS/MS using a 6520
Q-TOF mass spectrometer coupled online with a 1200 series
HPLC system through a Chip Cube Interface (Agilent
Technologies, CA, USA). Five ml of each sample were loaded
onto a C18 large capacity chip-column that integrates a 160 nl
capacity trap-column, a RP column (75 mm6150 mm),
connection capillaries, and nanospray emitter. Peptides were
separated with a linear gradient of 0–50% of solvent B in 50 min
at a flow rate of 0.5 ml/min. Solvent A was water/formic acid
0.1%, while solvent B was acetonitrile/formic acid 0.1%. Mass
spectra were acquired in a data dependent mode: MS/MS spectra
of the 3 most intense ions were acquired for each MS scan in the
range of 350–2400 Da. Scan speed was set to 4 MS spectra/sec
and 3 MS/MS spectra/sec. Capillary voltage was set to 1750 V
and drying gas to 5 l/sec. Raw data files were converted into
Mascot Generic Format (MGF) files with MassHunter Qualitative
Analysis Software (Agilent Technologies) and analyzed using
Proteome Discoverer Software (version 1.2, ThermoFisher
Scientific, CA, USA) as described below. Starting from the
confidently identified peptides, an excluding list was made for each
sample and the LC-MS/MS analysis was repeated using the same
chromatographic conditions and the same acquisition method.
The new raw data files were then converted into MGF format and
merged with the previous acquired files in order to obtain a single
MGF file for each sample.
Data analysis. The MGF files were analyzed using Proteome
Discoverer 1.2 (Thermo Fisher Scientific). The software was
connected to a Mascot Search Engine server version 2.2.4 (Matrix
Science, London, UK) and to a Sequest Search Engine version
28.0 (ThermoFisher Scientific). Spectra were searched against the
IPI Human database (version 24 February 2010, 86719 entries)
with the following parameters: enzyme specificity was set to
Trypsin with up to 2 missed cleavages, peptide and fragment
tolerance were set to 10 ppm and 0.05 Da respectively. Oxidation
of Methionine was selected as variable modification. False
Discovery Rates (FDR) of 0.5% and 0.1% were calculated by
Proteome Discoverer based on the search against the
corresponding randomized database. Before the search, data
were filtered to exclude MS/MS spectra containing less than 5
peaks and with a total ion count lower than 50. MGF files were
searched against Mascot only, or against Mascot and Sequest
followed by merging the results into a single list of peptides and
proteins. For Sequest analysis, peptides were validated after
meeting the following criteria: the cross-correlation score had to be
$1.9 for +2 tryptic peptides, $2.5 for +3 and +4 tryptic peptides
for medium confidence, while for high confidence identifications
XCorr should be be $2 for +2 tryptic peptides and $2.8 for +3
and +4 tryptic peptides. Identified peptides were classified as high
(99%) and medium (95%) confidence, according to the
corresponding FDR.
Proteins were considered as positive hits if at least two peptides
with medium confidence were identified per protein or if one
peptide was identified with high confidence. Results are reported
as single identified proteins or as protein groups, i.e. the minimum
set of protein sequences that adequately accounts for all observed
peptides.
Results
The experimental workflow is presented in Figure 1. We
compared the results obtained with analyses of a plasma proteome
derived from an immunoaffinity depletion of 20 highly abundance
proteins and the enrichment of low abundance proteins by
chemical hexapeptide libraries. Moreover, a multi-step depletion
was also performed, as described in the methods section. For each
fractionation approach, the number of peptides, proteins, and
protein groups identified by 1 (95% and 99% confidence), 2, and
.2 (95% confidence) peptides are reported in Table 1. Our
analyses led to an average identification of a few hundred proteins,
a result that is in line with those published in similar studies [8,23].
However, the number of identified proteins varies significantly
depending on the criteria chosen to consider the identification as a
positive hit (% confidence and minimum number of peptides per
protein). For each experimental approach, the complete list of
identified proteins is reported in Table S1 of supplemental data.
Considering the complexity of the dataset and the high
variability due to the different criteria, we decided to focus the
discussion on the number and type of protein groups identified
with 99% confidence and one peptide per protein [29].
Using these criteria, the merging of all sets of data allowed to
identify a total of 279 protein groups (Table S1). The average
sequence coverage calculated for the three methods gave very
similar results.
Discussion
The most straightforward result of this study, as can be deduced
from Table 1, is the lower efficacy of the ProteoMiner approach in
terms of total number of proteins identified, while the immuno-
depletion and the multi-step depletion approaches led to a similar
number of positive identifications. The same result was found for
the total number of peptides. What is striking to notice is the
number of proteins or protein groups that are identified with only
one significant peptide. In average, for about 30% of the proteins,
only one specific peptide was sequenced (compare columns 4 and
Depletion vs Enrichment for Plasma Proteome Study
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in other studies, where the contribution of single peptide
identifications is also quite large [30,31].
Although the enrichment method led to a lower number of protein
identifications, the protocol is much simpler and faster compared to
the depletion approach and requires less sample manipulations. This
advantage of the enrichment over the depletion protocol is evident
when considering the number of contaminant proteins (typically
keratins) that were identified. The keratin contamination is almost
negligible in the plasma sample treated with ProteoMiner, while for
the sample depleted with ProteoPrep20, keratin peptides account for
almost 10% of the total number. This can be ascribed to the very
laborious procedure of plasma depletion that requires a heavy and
time-consuming handling of the sample. Obviously, to allow such a
comparison, the operator, the quality of reagents, and the technical
precautions were identical for both approaches and the 2 procedures
were conducted in parallel.
Moreover, the protocol suggested by the supplier of Proteo-
Prep20 indicates, as an optional step, the precipitation of proteins
prior to trypsin digestion and MS analysis (i.e. after the depletion
procedure). We clearly verified that such a procedure cannot be
considered as optional because of the high amount of polymeric
compounds released by the depletion column that strongly
interferes with the MS analysis by suppressing peptide ionization.
We could demonstrate that plastic contaminants are released into
the sample not only from the depletion column itself, but also
when filtering the plasma at the preliminary step and when
concentrating the final depleted sample with the provided
concentrator (see methods section). An example of base peak
chromatograms obtained after each step of the depletion protocol
applied to an ultra-pure water sample and a characteristic MS
spectrum of the contaminants are shown in supplementary Figure
S1.
Table 2 reports the number of peptides, proteins and protein
groups that were identified with at least one peptide and 99%
confidence with Mascot, Sequest and the combination of the two.
Our results show that Sequest clearly outperforms Mascot in terms
of number of peptides identified. A manual screening of the
identified peptides suggests that Sequest is able to identify more
modified peptides (Met-Ox) and more often identifies the same
peptides with different charge states, while Mascot generally fails
to do so. However, by looking at the MS/MS spectra, it is possible
to deduce that Sequest is less stringent in terms of spectral quality.
A partial overlapping of the results could be observed, but an in-
depth statistical analysis should be performed in order to
characterize the common features of the peptides that are better
identified by one or the other of the search engines. The
combination of the two types of software does not increase
significantly the total number of proteins identified, but it
positively affects the average sequence coverage.
Figure 1. Experimental workflow.
doi:10.1371/journal.pone.0019603.g001
Table 1. Number of peptides, proteins, and protein groups identified by 1 (95% and 99% confidence), 2, and .2 (95% confidence)
peptides for each fractionation approach.
Fractionation approach
n6 of peptides
(95% conf) n6 of proteins (protein groups) identified
1 peptide
(95% conf) 1 peptide (99% conf) 2 peptides (95% conf)
.2 peptides
(95% conf)
ProteoMiner 2370 484 (195) 318 (139) 197 (90) 143 (66)
ProteoPrep20 3966 557 (271) 334 (186) 226 (130) 157 (92)
ProteoExtract+ProteoPrep20 3670 644 (239) 429 (163) 271 (123) 195 (92)
doi:10.1371/journal.pone.0019603.t001
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multi-step approach (enrichment/depletion, SCX, RP-LC-MS/
MS), highlights the difficulty of analysing the plasma proteome.
The merging of all sets of data allowed the identification of a total
of 279 unique protein groups with a 99% confidence. However,
our aim was not to develop a protocol for the identification of the
maximum number of proteins in plasma, but rather to evaluate
which of the two methods, between HAPs depletion and LAPs
enrichment, is more suitable as the first step for a plasma
proteomic analysis.
Despite the different number of identifications, all the
fractionation approaches primarily led to the detection of proteins
related to acute phase reaction, and complement and coagulation,
including proteins which can be classified as high- (1–100 mg/ml)
and mid- (0.1–1 mg/ml) abundance plasma proteins.
To show the overlap among the fractionation methods, we
report in Figure 2 a Venn diagram of the protein groups identified
with 99% confidence and one peptide per protein. From this
diagram it is clear that the three experimental protocols are
complementary: only 69 protein groups are common to all the
approaches, which represent only 37, 42, and 50% of all groups
associated to ProteoPrep20, ProteoExtract+ProteoPrep20, and
ProteoMiner respectively. By looking at the list of proteins
identified and the Venn diagram, we conclude that the great
majority of proteins, regardless the fact that they are identified
with one or more methods, belong to the above mentioned
categories. Therefore, all methods yielded similar performance in
terms of concentration range of identified proteins.
These data may suggest that the depletion and the enrichment
methods we have compared exhibit a similar performance and
lead to partially overlapping results. However, there are several
other aspects to be taken into account.
The aim of a plasma proteome analysis is to study proteins with
a concentration under 100 ng/ml, so other steps will necessarily
follow the first to improve sensitivity of the analysis. In this regard,
the use of ProteoPrep20, as a first-line fractionation step, does not
seem very practical. The major limit of this depletion kit is its
reduced plasma loading capacity of only 8 ml. In fact, the amount
of proteins obtainable after ProteoPrep20 depletion is of only
17 mg, which can be a limit for performing further fractionations.
Since the ProteoPrep20 column is recyclable up to 100 times, one
possibility could be to repeat the depletion many times and pool
the depleted fractions, with the inconvenience of time consuming
and extensive manipulation (with an increasing risk of introducing
errors and contaminations, as already discussed above). For the
sake of completeness it is important to report here that
ProteoPrep20 is also commercially available in form of a LC
column that has a much larger loading capacity than the small
columns provided with the immunodepetion kit used in this study.
Such LC columns can be loaded with up to 100 ml of plasma, are
reusable up to 100 times and are probably not subjected to the
release of polymeric compounds if properly conditioned. However,
ProteoPrep20 LC column has an estimated cost of 12,000 J and
therefore it is not easily affordable.
Another point to consider is the following: after using the multi-
affinity system, among the unbound identified proteins, we
detected with high coverage almost all the 20 proteins that should
have been depleted (Table S1). This undesired effect probably
depends on the fact that the column-bound antibodies although
polyclonal, do not recognize all isoforms and fragments of the 20
HAPs, or because the quantity of the HAPs saturates and exceeds
the column binding capacity (even when not overloaded). In an
attempt to improve the depletion approach, we decided to make a
first depletion with the ProteoExtract columns which are able to
retain 70% of HSA and IgG, starting from 60 ml of plasma. Since
these columns use an affinity resin and not antibodies, we thought
they could be used in a complementary way with ProteoPrep20 to
eliminate, at least, the largest possible amount of HSA and IgG.
Moreover, thanks to this first depletion, we aimed at loading into
the ProteoPrep20 column a larger amount of LAPs compared to
the undepleted plasma. The HSA and IgG depleted sample was
divided into several aliquots which were then depleted by
ProteoPrep20 column one by one. Thereafter, these eluates were
pooled, concentrated and depleted again with ProteoPrep20. Even
this multi-step depletion approach did not allow the complete
removal of high abundance proteins, although the number of
peptides belonging to these proteins was reduced. Moreover,
Table 2. Number of peptides, proteins and protein groups that were positively identified with at least 1 peptide and 99%
confidence with Mascot, Sequest and the combination of the two search engines.
Fractionation approach MASCOT SEQUEST MASCOT+SEQUEST
Peptides Proteins Protein Groups Peptides Proteins Protein Groups Peptides Proteins Protein Groups
ProteoMiner 363 147 72 1551 305 136 1914 318 139
ProteoPrep20 897 232 131 1798 323 183 2695 334 186
ProteoExtract+ProteoPrep20 861 258 112 1668 418 161 2529 429 163
doi:10.1371/journal.pone.0019603.t002
Figure 2. Venn diagram. The diagram shows the overlap of protein
groups identified after the different plasma fractionation approaches.
doi:10.1371/journal.pone.0019603.g002
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peptides and proteins, the average sequence coverage, and the
sensitivity limit of the analysis were similar compared to those
obtained after a single depletion with ProteoPrep20 (see Table 1).
A further attempt to improve the analyses, by analyzing again
the same samples using the same parameters and chromatographic
conditions, but applying an exclusion list (see Materials and
Methods, section 2.6) resulted only in the increase of the percent
coverage of some proteins already identified.
This partly confirms that, to dig deeper into the plasma
proteome, the most appropriate strategy of analysis is to include
additional steps and separate proteins on the basis of many
different criteria, such as the specific capture of glycol- and
cysteinyl-peptides [32,33].
While ProteoPrep20 kit was developed specifically for the
plasma analysis, the ProteoMiner approach, even if it is a
relatively recently developed technology, has already been
applied to the study of proteome from urine [34], serum
[35,36], platelets [37], and red blood cells [38]. This novel
fractionation method employs a large, highly diverse bead-based
library of combinatorial peptide ligands, which simultaneously
reduces HAPs and enriches LAPs.
The recovery of proteins after LAPs enrichment is approxi-
mately 3%, which is the same recovery obtained after the
ProteoPrep20 depletion. In terms of amount of proteins, however,
ProteoMiner allows obtaining a quantity 150 times greater and
this depends on the high capacities of the column (1 ml). Although
LAPs enrichment led to the identification of fewer proteins (about
25%) with respect to ProteoPrep20 depletion, we must take into
account the great advantage of obtaining sufficient material that
can still be subjected to further analysis. The reduced plasma load
capacity of immunodepletion column and the subsequent necessity
to reuse them many times is a common feature of all the
commercially available depletion kits [39].
Most authors who have recently conducted similar studies
using other protocols and kits, but always comparing LAPs
enrichment vs HAPs depletion as the first step of their protocol,
have concluded that the two methods are complementary, as
their records indicate that these methods allow to obtain similar
and only partially overlapping results [8,23,24]. From these
statements a very interesting and stimulating debate may
emerge. We speculate that the idea of combining the two
techniques in a complementary way is not feasible. We retain
the view that, for practical aspects, the LAPs enrichment
approach is an appealing fractionation technique. Indeed, given
the huge amount of work that a proteomic analysis of plasma
requires, it is preferable to develop a single orthogonal protocol
consisting of several steps to detect the proteins in the 100 ng/
ml range, rather than create and merge results from multiple
parallel analyses, because each single analysis might not reach
the desired sensitivity level.
Despite the continuous development of columns able to deplete
more and more HAPs simultaneously with the aim to reach the
low-abundance plasma protein range (,100 ng/ml), the ap-
proach of raising the number of antibodies may become a
prohibitively expensive (and never-ending) strategy, with a
parallel increase of nonspecific binding, which is a critical
concern in using immunoaffinity columns [9,12,30,40,41]. This
setback is such that some authors have recently stated that
increasing the number of antibodies from twelve to twenty has a
limited beneficial impact, while significantly increasing the risk of
removing peptides and proteins associated to the depleted
proteins [12]. This risk is linked to the fact that, in non-
denaturing conditions, the immunocaptured proteins that are
known to function also as carriers remain associated with several
peptides and proteins.
On the other hand, literature data have already shown a high
degree of reproducibility of ProteoMiner beads, with a lower
variability than other fractionation approaches, such as immuno-
depletion and gel filtration [26].
Finally, the workload and the cost to obtain the same protein
quantity after fractionation by LAPs enrichment is significantly
lower than performing the ProteoPrep20 immunodepletion
(Table 3). Altogether, the ProteoMiner technology emerges as an
attractive and convenient approach for plasma proteome analysis,
especially as the first step of a complex orthogonal protocol.
Supporting Information
Table S1 Proteins identified with at least 1 peptide and 99%
confidence. The accession numbers, and the depletion/enrich-
ment methods applied are also reported.
(XLS)
Table S2 All the peptides belonging to the proteins listed in
Table S1 are reported in Table S2, together with their sequences,
experimental masses, the difference between calculated and
measured masses (expressed in ppm), possible variable modifica-
tions, ion scores, expectation values, ranking for Mascot searches,
and XCorr, probability and ranking for Sequest searches.
(XLS)
Figure S1 Polymeric contamination. Examples of base peak
chromatograms obtained after each step of the depletion protocol
applied to an ultra-pure water sample. The polymeric contami-
nation was observed after each step of the ProteoPrep20 depletion
protocol applied to an ultra-pure water sample. Base Peak
Chromatogram of: (A) a water sample; (B) water passed through
the filter provided with the kit; (C) water passed through the
depletion column; (D) water passed through the provided
concentrator. (E) Example of the MS spectrum of contaminant
species released into the sample.
(TIF)








recovery Cost (J) per Time (hours) required per
kit 1000 ml plasma a single use 1000 ml plasma
ProteoMiner
(large capacity kit)
10 Single use 1000 ml
(,70 mg of proteins)
,3,7%
(,2.6 mg)
663 ,60 3 3
ProteoPrep20 1 100 8 ml
(,560 mg of proteins)
,3%
(,17 mg)
1090 ,1300 0.5 62.5
doi:10.1371/journal.pone.0019603.t003
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